Company intelligence / Profile preview

Opella Healthcare

Neuilly-sur-Seine, Île-de-France, France

Ownership: Private
Employees: ~11000
Development stage: Other

Overview

Opella is the world's third-largest player in over-the-counter (OTC) and vitamins, minerals, and supplements (VMS), with a commercial portfolio of 100 brands, including Allegra (fexofenadine), Doliprane (paracetamol), Buscopan (hyoscine butylbromide), and Dulcolax. It is actively pursuing the prescription-to-OTC switch for tadalafil (Cialis), recently gaining FDA clearance for a US OTC study. It was formerly Sanofi's consumer healthcare business and is now co-owned by CD&R, Sanofi, and Bpifrance.

Therapeutic areas: ImmunologyNeurologyMen's HealthGastroenterology
Modalities: Small molecule
Industry: Pharma

Partnerships

SanofiEli Lilly (OTC Cialis agreement)

Beyond the preview

Go deeper on Opella Healthcare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Opella Healthcare.

Explore the full profile